{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graft+vs.+Host+Disease&page=12",
    "query": {
      "condition": "Graft vs. Host Disease",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 831,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graft+vs.+Host+Disease&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graft+vs.+Host+Disease&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T00:09:29.902Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03657160",
      "title": "Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hematopoietic Stem Cells"
      ],
      "interventions": [
        {
          "name": "Vedolizumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 343,
      "start_date": "2019-02-06",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657160"
    },
    {
      "nct_id": "NCT03128359",
      "title": "High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Diffuse Large B-Cell Lymphoma",
        "Follicular Lymphoma",
        "Graft Versus Host Disease",
        "Hodgkin Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "5 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2017-05-30",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-01-09",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03128359"
    },
    {
      "nct_id": "NCT02248597",
      "title": "Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Hematopoietic/Lymphoid Cancer"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 27,
      "start_date": "2015-02-25",
      "completion_date": "2023-01-18",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02248597"
    },
    {
      "nct_id": "NCT06950060",
      "title": "AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stroke, Chronic",
        "Aging",
        "Cognitive Decline",
        "Motor Dysfunction",
        "Neuroplasticity"
      ],
      "interventions": [
        {
          "name": "High intensity cycling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Low-intensity cycling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health education session",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Moderate Intensity Aerobic Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 48,
      "start_date": "2026-07-15",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06950060"
    },
    {
      "nct_id": "NCT01111526",
      "title": "Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft-Versus-Host Disease"
      ],
      "interventions": [
        {
          "name": "Panobinostat (LBH589)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2010-04",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-05-15",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01111526"
    },
    {
      "nct_id": "NCT02281084",
      "title": "Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Oral Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2015-07-06",
      "completion_date": "2023-09-14",
      "has_results": true,
      "last_update_posted_date": "2024-10-04",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 23,
      "location_summary": "New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281084"
    },
    {
      "nct_id": "NCT00832585",
      "title": "Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Alefacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2008-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2011-03-10",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00832585"
    },
    {
      "nct_id": "NCT00382109",
      "title": "Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "B-cell Childhood Acute Lymphoblastic Leukemia",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Graft Versus Host Disease",
        "L1 Childhood Acute Lymphoblastic Leukemia",
        "L2 Childhood Acute Lymphoblastic Leukemia",
        "T-cell Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sirolimus",
          "type": "DRUG"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 146,
      "start_date": "2007-03",
      "completion_date": "2017-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Duarte, California • Oakland, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00382109"
    },
    {
      "nct_id": "NCT03154541",
      "title": "SynRinse Irrigation Pilot (SIP) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sinusitis, Chronic",
        "Cystic Fibrosis With Other Manifestations"
      ],
      "interventions": [
        {
          "name": "Synrinse",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-06-06",
      "completion_date": "2018-05-30",
      "has_results": false,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03154541"
    },
    {
      "nct_id": "NCT05866302",
      "title": "Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Lung Disease",
        "Hematopoietic Cell Transplantation",
        "Graft Versus Host Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "36 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "36 Months and older"
      },
      "enrollment_count": 375,
      "start_date": "2023-05-30",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-14T00:09:29.902Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Atlanta, Georgia • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05866302"
    }
  ]
}